General Control develops programmable epigenetic editing medicines that can precisely up‑ or down‑regulate multiple genes at their native loci in a single treatment. By using synthetic transcription factors to edit chromatin, the platform enables coordinated, durable modulation of disease‑relevant gene networks for age‑related and multifactorial conditions, offering biopharma partners a way to target complex phenotypes beyond the reach of traditional single‑protein drugs.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related and multifactorial diseases such as Alzheimer’s and sarcopenia involve complex networks of gene expression changes, yet existing therapeutics target single proteins and cannot efficiently modulate multiple disease nodes simultaneously.
Solution
General Control develops programmable epigenetic editing medicines that can up‑ or down‑regulate any gene at its native locus, with precise dosage, durability, and the ability to combine multiple gene targets in a single treatment. By using synthetic transcription factors that edit chromatin, the platform delivers coordinated, locus‑specific control of several disease‑relevant genes, enabling one‑time interventions that replace chronic dosing. The technology is designed to preserve cellular identity while providing lasting adjustments to gene networks implicated in aging and chronic disease. This approach expands the druggable genome to include targets previously inaccessible to small molecules, antibodies, or gene‑therapy vectors.
Target Audience
Primary customers are biopharmaceutical companies and research organizations developing treatments for age‑related, neurodegenerative, and musculoskeletal diseases that require multi‑gene modulation.
Features
- Miniature epigenetic activators that stably up‑regulate genes at native loci, outperforming recombinant protein benchmarks
- Chromatin‑level silencing tools that achieve durable gene repression with a single administration
- Multiplexed editing capability allowing simultaneous modulation of multiple genes within one therapy
- Tunable expression control to set target gene levels, duration, and combination ratios
- Safety architecture that maintains cellular identity and minimizes off‑target effects
- Platform designed for scalability across the entire human genome, enabling rapid development of new indications